Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

被引：0
|
作者：
Chunxia Qiao
Meiyun Hu
Leiming Guo
Ming Lv
Zhou Lin
Jing Geng
Xiaoling Lang
Xinying Li
Yan Li
Yuanfang Ma
Jiannan Feng
Beifen Shen
机构：
[1] Institute of Basic Medical Sciences,Department of Immunology
[2] Henan University,Laboratory of Cellular and Molecular Immunology, Institute of Immunology
来源：
BMC Immunology | / 13卷
关键词：
TRAIL; Death receptor 5; Monoclonal antibody; Apoptosis; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Increased expression of TRAIL and its death receptors DR4 and DR5 in plaque psoriasis
    Sandra Peternel
    Larisa Prpić-Massari
    Teo Manestar-Blažić
    Ines Brajac
    Marija Kaštelan
    Archives of Dermatological Research, 2011, 303 : 389 - 397
  • [32] Increased expression of TRAIL and its death receptors DR4 and DR5 in plaque psoriasis
    Peternel, Sandra
    Prpic-Massari, Larisa
    Manestar-Blazic, Teo
    Brajac, Ines
    Kastelan, Marija
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2011, 303 (06) : 389 - 397
  • [33] Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle
    Ren, YG
    Wagner, KW
    Knee, DA
    Aza-Blanc, P
    Nasoff, M
    Deveraux, QL
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (11) : 5064 - 5074
  • [34] Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding
    Bin, Lianghua
    Thorburn, Jacqueline
    Thomas, Lance R.
    Clark, Peter E.
    Humphreys, Robin
    Thorburn, Andrew
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (38) : 28189 - 28194
  • [35] Role of Endoplasmic Reticulum Stress in α-TEA Mediated TRAIL/DR5 Death Receptor Dependent Apoptosis
    Tiwary, Richa
    Yu, Weiping
    Li, Jing
    Park, Sook-Kyung
    Sanders, Bob G.
    Kline, Kimberly
    PLOS ONE, 2010, 5 (07):
  • [36] Requirement of both isoforms of TRAIL-R2 (DR5) in death receptor signaling.
    Peters, Kristi
    Yang, Ke
    DeVecchio, Jennifer
    Humphreys, Robin
    Houghton, Janet
    CANCER RESEARCH, 2009, 69
  • [37] Both TRAIL receptor DR5 isoforms are required for the induction of cell death in human colon carcinoma
    Jani, Tanvi S.
    DeVecchio, Jennifer
    Peters, Kristi
    Houghton, Janet
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [38] DR5 agonist activity of HexaBody®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models
    Overdijk, Marije B.
    Strumane, Kristin
    Buijsse, Antonio Ortiz
    Vermot-Desroches, Claudine
    Kroes, Thessa
    de Jong, Bart
    Hoevenaars, Naomi
    Beurskens, Frank J.
    de Jong, Rob N.
    Lingnau, Andreas
    Parren, Paul W.
    Forssmann, Ulf
    Sasser, A. Kate
    Schuurman, Janine
    Breij, Esther C.
    CANCER RESEARCH, 2019, 79 (13)
  • [39] Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
    Pavet, Valeria
    Beyrath, Julien
    Pardin, Christophe
    Morizot, Alexandre
    Lechner, Marie-Charlotte
    Briand, Jean-Paul
    Wendland, Miriam
    Maison, Wolfgang
    Fournel, Sylvie
    Micheau, Olivier
    Guichard, Gilles
    Gronemeyer, Hinrich
    CANCER RESEARCH, 2010, 70 (03) : 1101 - 1110
  • [40] Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer
    Arafat, Waleed
    Zhou, Tong
    Naoum, George E.
    Buchsbaum, Donald J.
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2015, 27 (04) : 205 - 215
12345